Remote monitoring of urinalysis parametres during treatment of patients with uric acid stones by citrate-containing compounds


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Introduction. Oral dissolution therapy has been successfully used in urologic practice since 1950s. However, many doctors attempt to improve efficiency of this approach. Use of different medical personalized digital devices which are increasingly used in clinical practice, represent one of the solutions of this problem. Aim. Our aim was to assess efficiency of oral dissolution therapy with drug Blemaren in patients with uric acid stones using of portable urinary analyzer with system of remote monitoring. Materials and methods. A total of 12 patients with uric acid stones were followed. All of them had kidney stone with a density less than 500 HU according to CT-urography. Oral dissolution therapy was performed with the drug Blemaren for 8-9 weeks. All patients were advised to maintain urine pH of 6.5-7.0. With aim of dynamic monitoring of urine parameters, a portable urine analyzer “ETTA AMP-01” was given to all patients for 2 months. Results. Complete dissolution was achieved in 10 (83.3%) patients. In one case (8.3%) oral dissolution therapy was complicated by acute pyelonephritis. A stenting was performed and dissolution therapy was continued with a positive effect. In another case (8.3%) partial dissolution was seen, however, extracorporeal shockwave lithotripsy was decided to perform. Doctor who remotely monitored different parameters of urinalysis (n=11) followed urine pH, density, leukocytes, erythrocytes, level of nitrite, which provided a more comprehensive assessment of patient’s current state. If necessary, the specialist contacted the patient and adjusted the therapy. Conclusion. The possibility of remote monitoring of urinalysis and simple communication with urologist allows to titrate drug dose more convenient compared to conventional approach when outpatient urologist controls pH diaries based on dip-stick test. Moreover, such approach gives an opportunity to quickly identify complications and correct the therapy in a timely manner.

全文:

受限制的访问

作者简介

M. Prosiannikov

N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - Branch of the National Medical Research Centre of Radiology of the Ministry of Health of Russian Federation

Email: prosyannikov@gmaiI.com
Ph.D., Head of Department of urolithiasis

I. Shaderkin

FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: info@uroweb.ru
Ph.D., urologist, Head of the e-Health Laboratory at the Institute of Digital Medicine

O. Konstantinova

N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - Branch of the National Medical Research Centre of Radiology of the Ministry of Health of Russian Federation

MD, Chief Researcher at the Department of urolithiasis

N. Anokhin

N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - Branch of the National Medical Research Centre of Radiology of the Ministry of Health of Russian Federation

Ph.D., Researcher at the Department of urolithiasis

D. Voytko

N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - Branch of the National Medical Research Centre of Radiology of the Ministry of Health of Russian Federation

Ph.D., Researcher at the Department of urolithiasis

A. Nikushina

N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - Branch of the National Medical Research Centre of Radiology of the Ministry of Health of Russian Federation

Ph.D., Head of Organizational and Methodical Department, scientific secretary

参考

  1. Каприн А.Д., Аполихин О.И., Сивков А.В., Солнцева Т.В., Комарова В.А. Анализ уронефрологической заболеваемости и смертности в Российской Федерации за 2002-2014 гг. по данным официальной статистики экспериментальной и клинической урологии 2016;3:4-13
  2. Yasui T., Iguchi M., Suzuki S., Kohri K. Prevalence and epidemiological characteristics of urolithiasis in Japan: national trends between 1965 and 2005. Urology. 2008;71:209-213.
  3. Scales C.D., Jr, Smith A.C., Hanley J.M., Saigal C.S. Urologic diseases in America project. Prevalence of kidney stones in the United States. Eur Urol. 2012;62:160-165.
  4. Stamatelou K.K., Francis M.E., Jones C.A., Nyberg L.M., Curhan G.C. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int. 2003;63:1817-1823.
  5. Ferraro P.M., Taylor E.N., Gambaro G., Curhan G.C. Dietary and Lifestyle Risk Factors Associated with Incident Kidney Stones in Men and Women J. Urol. 2017;198(4):858-863. doi: 10.1016/j.juro.2017.03.124.
  6. Kok D.J. The preventive treatment of recurrent stone-formation: how can we improve compliance in the treatment of patients with recurrent stone disease? Urolithiasis. 2016;44(1):83-90. doi: 10.1007/s00240-015-0842-9
  7. Remer T. Influence of nutrition on acid-base balance-metabolic aspects. Eur J. Nutr. 2001;40:214-220.
  8. Skolarikos A., Straub M., Knoll T., Sarica K., Seitz C., Petnk A., Turk C. Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. Eur Urol. 2015;67(4):750-763.
  9. Trinchieri A., Maletta A., Lizzano R., Marchesotti F. Potential renal acid load and the risk of renal stone formation in a case-control study Eur J. Clin Nutr. 2013;67(10):1077-1080. doi: 10.1038/ejcn.2013.155,
  10. Engberink M.F., Bakker S.J., Brink E.J., van Baak M.A., van Rooij F.,J., Hofman A. Dietary acid load and risk of hypertension: the Rotterdam Study Am J. Clin Nutr. 2012;95(6):1438-1444. doi: 10.3945/ajcn.111.022343,
  11. Adeva M.M., Souto G. Diet-induced metabolic acidosis Clin Nutr. 2011;30(4):416-421. doi: 10.1016/j.clnu.2011.03.008.
  12. Prien E.L. Studies in urolithiasis: III Physico-chemical principles in stone formation and prevention. J. Urol. 1955;73:627.
  13. Coe F.L. Nephrolithiasis pathogenesis and treatment. Year Book medical Publishers. Chicago-London, 1978.
  14. Ewans R.A., Maher P.O., Agostino M. Wong S.Y., Marel G.M., Hills E. Investigation and treatment ofrenal calculi. Med. J. Austr. 1985;143(7):278-281.
  15. Чудновская М.В., Даренков А.Ф., Яненко Э.К. и соавт. Методические рекомендации. Схемы лечения и профилактики мочекислого, кальций-оксалатного и кальций-фосфатного уролитиаза. М., 1992. 12 с.
  16. Пытель Ю.А., Золотарев И.И. Уратный нефролитиаз. М.: Медицина, 1995. 176 с.
  17. Rodman J.S. Intermittent versus continuous alkaline therapy for uric acid stones and ureteral stones of uncertain composition. Urology. 2002;60:378.
  18. Колпаков И.С. Мочекаменная болезнь. Пособие для врачей. М., 2006. 21 с.
  19. Клименко П.М., Чабанов В.А., Акиншевич И.Ю. Возможности консервативного лечения больных уратным нефролитиазом. Новости медицины и фармации. 2010;3:5-7
  20. Глыбочко П.В., Аляев Ю.Г., Рапопорт Л.М., Цариченко Д.Г., Фролова Е.А. Современная консервативная (цитратная) терапия при уратных камнях мочеточников. Урология. 2014;5:10-13
  21. Eisner B.H., Goldfarb D.S., Pareek G. Pharmacologic treatment of kidney stone disease. Urol Clin North Am. 2013;40(1):21-30.
  22. Шадеркин И.А., Владзимирский А.В., Цой А.А., Войтко Д.А., Просянников М.Ю., Зеленский М.М. Диагностическая ценность портативного анализатора мочи ЭТТА АМП-01 как инструмента самостоятельного мониторинга в mHealth и при скрининге в первичном звене медицинской помощи Экспериментальная и клиническая урология. 2015;4:22-26
  23. Константинова О.В., Яненко Э.К. Опыт применения Блемарена в лечении больных мочекислым и кальций-оксалатным уролитиазом. Урология. 2015;5:22-26

补充文件

附件文件
动作
1. JATS XML

版权所有 © Bionika Media, 2019
##common.cookie##